CliffBio
biologic

Norditropin

somatropin

Loss of exclusivityJanuary 2027projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameNorditropin
Active ingredientsomatropin
Strength30MG/3ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2015
Marketing statusRx

More from Novo Nordisk Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Norditropin patent cliff — loss of exclusivity January 2027 | CliffBio